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THE EFFICACY OF CITROLINE IN THE TREATMENT OF ISCHEMIC 
STROKE AND PRIMARY HYPERTENSIVE INTRACERERAL 







Stroke is a medical emergency with a mortality rate higher than most forms of cancer. It is the 
second leading cause of death in developed countries and the most common cause of serious, 
long-term disability in adults. 
Primary intracerebral hemorrhage (ICH) is a major clinical problem that accounts for 15% of all 
acute stroke hospitalizations. Currently, there is no medical therapy available for these patients, 
with options being limited to supportive care or invasive neurosurgical evacuation. The damage 
induced by an ICH appears to be related to a combination of different factors. In addition to 
direct  mechanical  disruption  from  the  hematoma,  surrounding  injury  secondary  to  edema 
formation  and  ischemia  are  contributing  factors  for  brain  injury  following  ICH.  Citicoline 
(cytidine-5-diphosphocholine) is an essential precursor for the synthesis of phosphatidylcholine 
that  is  key  component  of  cell  membranes.  Citicoline  is  a  naturally  occurring  endogenous 
compound. For clinical use, the sodium salt of this compound usually utilized. During ischemia, 
phosphatidylcholine is broken down into free fatty acids, which in turn are used to generate free 
radicals  that  potentiate  ischemic  injury.  Citicoline  is  a  neuroprotectant  drug  with  some 
beneficial effects in human ischemic stroke and primary intracerebral hemorrhage (ICH) with 
an excellent safety profile. 
In the current paper, we review published papers regarding use of citicoline in the treatment of 
human ischemic stroke and primary intracerebral hemorrhage (ICH). 
 
Keywords: Citicoline, Treatment, Ischemic Stroke, Intracerebral Hemorrhage 
 
ARYA Atherosclerosis Journal 2010, 6(3) 
Date of submission: 24 jul 2010, Date of acceptance: 19 Aug 2010 
 
Introduction 
Stroke is a medical emergency with a mortality rate 
higher than most forms of cancer. It is the second 
leading cause of death in developed countries and the 
most common cause of serious, long-term disability in 
adults.1 
  Primary intracerebral hemorrhage (ICH) is a major 
clinical problem that accounts for 15% of all acute 
stroke  hospitalizations.2  Mousavi  et  al.  mentioned 
Primary Hypertensive ICH and recurrence of that is 
an importance health problem.3 Currently, there is no 
medical  therapy  available  for  these  patients,  with 
options being limited to supportive care or invasive 
neurosurgical  evacuation.  Citicoline  (CDP-choline, 
cytidine  diphosphate  choline  or  cytidine  5’-
diphosphocholine)  belongs  to  the  group  of 
biomolecules  in  living  systems  recognized  as 
“nucleotides”  that  have  important  roles  in  cellular 
metabolism.4  
  Grouped  with  the  B  vitamins,  choline  is  a 
trimethylated  nitrogenous  base  that  goes  into  three 
major metabolic pathways: (1) phospholipid synthesis 
via phosphorylcholine; (2) acetylcholine synthesis; and 
(3)  oxidation  to  betaine,  which  serves  as  a  methyl 
donor.5 
  It  is  recognized  that  choline  enters  the  various 
biosynthetic  pathways  that  use  citicoline  as  an 
intermediate. Citicoline, therefore, has a sparing effect 
on systemic choline reserves, as well as inhibiting the 
breakdown of membrane phospholipids.6 
  Citicoline  is  a  water-soluble  compound  with 
greater  than  90-percent  bioavailability  and  is 
metabolized in the gut wall and liver.7 
  Studies  have  shown  that  citicoline  elimination 
occurs mainly through respiratory 
  CO2 and urinary excretion. The elimination half-
life  is  56 hours  for  CO2  and  71  hours for  urinary 
excretion.7   SA. Mousavi, F. Khorvash, T. Hoseini 
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  Four  different  mechanisms  of  action  have  been 
suggested for citicoline that include; 
  1-  They  have  a  role  as  a  phosphatidylcholine 
precursor (as has been shown in animal studies)8 and 
therefore  exogenous  citicoline  helps  preserve  the 
structural  and  functional  integrity  of  the  neuronal 
membrane. 
  2-  They  have  a  role  in  repair  of  neuronal 
membrane that makes them as a candidate for stroke 
therapy. The main mechanisms in this regards are; 
-  Repair  of  neuronal  membranes  via  increased 
synthesis of phosphatidylcholine. 
-  Repair  of  damaged  cholinergic  neurons  via 
potentiation of acetylcholine production. 
- Reduction of free fatty acid buildup at the site of 
stroke-induced nerve damage.9 
  3-  Citicoline  counteracts  the  deposition of beta-
amyloid, a neurotoxic protein, which believed to play 
a central role in the pathophysiology of Alzheimer’s 
disease.7 
  4- In human, it has been shown that citicoline can 
enhance norepinephrine release. Citicoline potentiates 
dopamine release in the brain of rats, presumably by 
stimulating release of acetylcholine.7 
  Post-stroke  rehabilitation,  ischemic  stroke, 
hemorrhagic  stroke,  dementia,  Alzheimer’s  disease, 
brain trauma, spinal cord injury, Parkinson’s disease, 
Huntington’s disease, bipolar disorder and associated 
substance abuse and finally glaucoma and amblyopia 
are regarded as clinical indications of citicoline. 
 
Efficacy of citicoline as an acute stroke treatment 
Numerous experimental studies with citicoline have 
shown improved outcome and reduced infarct size in 
ischemic stroke models .10 Citicoline has been studied 
worldwide  in  both  ischemic  clinical  stroke  with 
excellent safety and possibly efficacy found in several 
trials).11 
  Efficacy of 3 different doses of citicoline (i.e. 500 
mg, 1000 mg and 2000 mg) in 
  patients with acute ischemic stroke were evaluated 
by Clark et al.12 as a vehicle controlled double-blind 
trial.  Treatment  was  initiated  within  24  hours  of 
stroke onset and was continued orally for 6 weeks. 
No drug-related serious adverse events or deaths were 
reported  in  this  study.  The  authors  concluded  that 
oral citicoline could be used safely with minimal side 
effects in acute stroke treatment. 
  Clark et al.13 evaluated efficacy of citicoline (500 
mg  po  daily)  for  6  weeks,  with  a  6-week  post 
treatment follow-up period in the patients with acute 
ischemic  stroke  as  a  randomized,  double-blind, 
placebo-controlled  clinical  trial.  Only  patients  with 
acute ischemic strokes in the middle cerebral artery 
territory with NIHSS > or = 5 were enrolled. Their 
results  indicated  that  citicoline  was  safe,  but 
ineffective in improving the outcome of patients with 
acute ischemic stroke who were enrolled in this trial. 
However, the authors concluded that citicoline might 
be useful in patients with moderate strokes. 
   In  another  randomized,  double-blind  trial,  899 
patients  with  acute  stroke  were  randomized  to  be 
treated either with placebo or with citicoline (1000 mg 
po  twice  a  day)  for  6  weeks,  with  a  6-week  post-
treatment follow up period. Patients with acute (< or 
=24 hours) ischemic strokes clinically thought to be 
in  the  middle  cerebral  artery  territory  with  NIH 
Stroke Scale (NIHSS) scores > or =8 were evaluated. 
The authors concluded that citicoline was safe, but 
ineffective in improving the outcome of patients with 
acute  ischemic  stroke  as  measured  by  the  planned 
analyses.14 
  A  systematic  search  of  all  prospective, 
randomized, placebo-controlled, double-blind clinical 
trials  with  oral  citicoline  was  also  performed  by 
Davalose et al.4 
  They  reviewed  four  clinical  trials  using  different 
doses of oral citicoline (i.e. 500, 1000, and 2000 mg). 
Out of 1652 randomized patients, 1372 fulfilled the 
inclusion criteria (583 received placebo, 789 received 
citicoline).  Recovery  at  3  months  was  25.2%  in 
citicoline-treated  patients  and  20.2%  in  placebo 
treated patients (P = 0.0034). 2000 mg of citicoline 
showed  the  largest  difference  with  placebo  with 
27.9% of patients achieving recovery (P = 0.0043). 
  No significant difference regarding side effect was 
observed  between  the  two  groups.  The  authors 
concluded that treatment with oral citicoline within 
the  first  24  hours  after  onset  in  patients  with 
moderate to severe stroke increases the probability of 
complete recovery at three months period.15 
  Mousavi et al. selected patients who had cortical 
infarction  in  the  middle  cerebral  artery  territory 
(superior  or  inferior  division)  with  moderate 
neurologic deficits (Orgogozo scale score greater than 
30 and less than 70) and onset less than 24 hours. The 
patients were treated with citicoline (500 mg bid) for 
seven days and examined by a blind investigator. NIH 
stroke  scale  and  orgogozo  index  were  obtained  on 
admission  and  compared  with  Barthel  index  and 
Rankin score in 90 days after stroke. 20 patients were 
treated and 20 patients were left untreated as controls. 
Significant difference in Barthel index was observed 
90 days after stroke between two groups. The authors 
concluded that intravenous citicoline had significant 
beneficial effect on acute phase of stroke patients and 
this  compound  might  be  helpful  for  reduction  of 
morbidity and disability of the stroke patients.16 THE EFFICACY OF CITROLINE 
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  In  experimental  stroke  models,  citicoline 
conferred  acute  neuroprotection  and  enhanced 
neuroplasticity  and  neurorepair  in  the  subacute 
period. Although individual human stroke trials have 
been inconclusive, meta-analysis of 10 trials enrolling 
2279 patients suggests patients receiving citicoline had 
substantially  reduced  frequencies  of  death  and 
disability.11 
  Considering the aforementioned studies regarding 
efficacy of citicoline and its safety profile, it seems 
logical to use this medication in patients with acute 
phase of stroke.  
 
Efficacy  of  citicoline  as  a  hemorrhagic  stroke 
treatment 
There are only few studies regarding use of citicoline 
for  patients  with  ICH.  Clark  et  al.2  evaluated  the 
efficacy of citicoline in reduction of ischemic injury 
and  improvement  of  the  functional  neurological 
outcome in an experimental model of ICH. ICH was 
induced  by  collagenase  injection  into  the  caudate 
nucleus  in  68  Swiss  albino  mice.  These  mice  were 
randomized to receive either citicoline 500 mg/kg or 
saline IP prior to collagenase at 24 and 48 hours. Mice 
were  rated  on  a  28-point  neurological  scale  and 
sacrificed at 54 hours. The brains were sectioned, and 
the  volume  of  hematoma,  total  lesion,  and 
surrounding  ischemic  injury  was  determined. 
Regarding functional  outcome,  animals treated  with 
citicoline had improved neurological outcome scores 
compared with placebo-treated animals (P < 0.01). In 
terms  of  ischemic  injury,  animals  treated  with 
citicoline  had  a  smaller  surrounding  volume  of 
ischemic  injury  than  placebo-treated  animals  (P  < 
0.05).  However,  there  was  no  difference  in  the 
underlying hematoma volumes.  
  The  authors  concluded  that  treatment  with 
citicoline  significantly  improved  functional  outcome 
and  reduced  the  volume  of  ischemic  injury 
surrounding the hematoma2. 
  Safety  and  efficacy  of  citicoline  in  human  with 
intracerebral haemorrhage was evaluated by Secades 
et al.17 as a pilot study. In this double-blind, placebo-
controlled  study,  patients  with  acute  primary 
supratentorial hemispheric cerebral haemorrhage were 
selected and received either a placebo or 1 g/12 h 
citicoline for 2 weeks (orally or intravenously). The 
efficacy endpoint was the percentage of patients with 
a  modified  Rankin  Score  (mRS)  at  3  months.  The 
incidence of serious adverse events was not different 
among groups (4 patients in each group). One patient 
in the placebo group was categorized as independent 
(mRS < or = 2) in comparison with 5 patients in the 
citicoline  group  (OR,  5.38;  95%  CI,  0.55-52).  The 
authors concluded that citicoline was a safe drug in 
human intracerebral hemorrhage with a positive trend 
regarding efficacy .17 
  Mousavi  et  al.  evaluated  40  patients  aged  older 
than  40-years  old  with  acute  symptoms  of 
supratentorial  hemorrhage  and  onset  of  symptoms 
less  than  6  hours.  Cases  group  were  treated  with 
citicoline (1000 mg bid) for 14 days and control group 
were treated with placebo. 
  At  the  end  of  study  (at  day  90),  patients  were 
examined again for NIHSS, GCS s and Barthel index. 
There  was  significant  difference  regarding  Barthel 
index between the two groups in favor of citicoline 
group  (p  =  0.008).  The  authors  concluded  that 
citicoline  can  improve  neuralgic  function  and  can 
decrease symptoms of ICH.Very few patients showed 
side effects following treatment with citicoline .18 
  Overall, it seems that still there are not enough 
evidences to use citicoline in the treatment of human 
intracerebral  hemorrhage.  More  randomized  clinical 
trials with larger sample size are required to confirm 
the efficacy and safety of this medication for patients 
with ICH. 
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